Isoplex (Succinylated Gelatin)

Succinylated gelatin forms a hydrated polymer network that increases viscosity and creates a protective environment for labile molecules. The succinyl groups reduce immunogenic potential while preserving gelatin’s ability to bind water, thereby preventing aggregation and degradation of the active pharmaceutical ingredient.

The amount of Isoplex required in a formulation is determined by the prescribing manufacturer or formulation scientist. Dosage is based on the specific product, concentration needed for stability, and regulatory guidelines, and is not a fixed therapeutic dose.

Succinylated gelatin is generally considered inert, but safety data for use in pregnant or lactating patients are limited. The decision to use products containing Isoplex should be made by the healthcare provider after evaluating potential risks and benefits for mother and child.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Isoplex. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Isoplex uses succinylated gelatin, which offers reduced immunogenicity compared with native gelatin while maintaining similar stabilising properties. This can lower the risk of allergic reactions in sensitive patients, making it a preferred choice for formulations where gelatin hypersensitivity is a concern.

Isoplex should be stored at ambient temperature, below 25 °C, in its original container. Protect the product from moisture, direct sunlight and extreme temperature fluctuations to preserve its functional integrity.

Isoplex is not administered directly to patients; it is incorporated into the final drug, vaccine or diagnostic product by the manufacturer. The finished product is then given to the patient according to the specific administration route of that product (e.g., injection, infusion).

The most serious risks involve hypersensitivity reactions, including anaphylaxis, especially in individuals with known gelatin allergies. Rare serum‑sickness‑like symptoms and bronchospasm have also been reported. Immediate medical attention is required if severe allergic signs appear.

Patients with a documented allergy to gelatin or related proteins should avoid products containing Isoplex. Additionally, formulations that are chemically incompatible with gelatin‑based excipients should not be combined with Isoplex without appropriate stability testing.